About 5% of all cancers worldwide are caused by human papillomaviruses (HPV). The present treatment for those cancers comprises surgery and/or radiochemotherapy. No targeted therapy against those tumors is currently available. We have identified a molecular mechanism by which HPV alters the cells to become malignant and identified a class of drugs that may revert this situation.
It is known that patients may react very differently to cancer treatment even if they all have the same type of cancer.
In this study, we intend to identify novel biomarkers that may allow us to assess which patients are most likely to benefit from our new treatment approach.